Gil Yosipovitch, MD
Dermatology · Miami, FLNPI 1679558027
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $701,617 of the $1,049,705 with a category attached, or 66.8%. 35 manufacturers reported payments, led by Sanofi at 32.6% of the total. Among dermatology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 633 payments — averaging $1658.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$342K
- Pfizer$92K
- Novartis$88K
- Galderma Laboratories, L.p.$79K
- Regeneron Healthcare Solutions, Inc.$68K
- Eli Lilly$67K
- plus $314K from 29 others
Across 436 payments — averaging $6728.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1.2M
- Sanofi$1M
- Regeneron$168K
- Pfizer$153K
- Sanofi US Services Inc.$133K
- LEO Pharma Inc.$101K
- plus $181K from 9 others
What the payments were for
- Consulting fees$701,61767%
- Speaking & faculty fees$211,99720%
- Travel & lodging$117,02911%
- Food & beverage$19,0432%
- Education$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,049,705 in reported general payments places this provider in the 95th percentile of 1,147 dermatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 47 | $193,872 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 20 | $187,470 |
| Dupixent SyringeDupilumab | 16 | $61,590 |
| Pregabalin | 129 | $2,238 |
| Gabapentin | 55 | $1,346 |
| Butorphanol Tartrate | 26 | $1,001 |
| Clobetasol Propionate | 22 | $925 |
| Mometasone Furoate | 40 | $749 |
| Pentoxifylline | 23 | $731 |
| Ketoconazole | 52 | $592 |
| Fluocinonide | 19 | $564 |
| Mirtazapine | 75 | $537 |
| MethotrexateMethotrexate Sodium | 69 | $421 |
| Minocycline Hcl | 11 | $195 |
| Triamcinolone Acetonide | 11 | $187 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Miami
- Francisco KerdelMiami$2.1M
- Robert KirsnerMiami$1.4M
- Mercedes GonzalezMiami$943K
- Heather Woolery LloydMiami$609K
- Hadar Lev-TovMiami$326K
- Lawrence SchachnerMiami$309K
- Giovanna CioccaMiami$222K
- Janice Lima MaribonaMiami$217K
- Jill WaibelMiami$116K
- Ana DuarteMiami$107K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.